Rituximab in Refractory Myasthenia Gravis – Challenges and Lessons Learnt
Nearly 10%–15% patients with generalized myasthenia gravis (MG) have refractory disease and are candidates for newer nonconventional immunotherapies. Rituximab has emerged as an attractive option in them. We describe the efficacy and safety of rituximab in 12 patients with refractory MG treated over...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | Annals of Indian Academy of Neurology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/aian.aian_579_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|